Verocytotoxin-producing Escherichia coli, Japan, 1999–2004

by Mio Sakuma, Mitsuyoshi Urashima, Nobuhiko Okabe
Published 2006-02-01

The Burden of Preventable Adverse Drug Events on Hospital Stay and Healthcare Costs in Japanese Pediatric Inpatients: The JADE Study

by Hitoshi Iwasaki, Mio Sakuma, Hiroyuki Ida, Takeshi Morimoto
Published 2021-02-01

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

by Atsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Shinichiro Ueda, Koichi Node
Published 2019-11-01

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (R...

by Hiroyuki Hirai, Moritake Higa, Takeshi Morimoto, Mio Sakuma, Osamu Arasaki, Takashi Nomiyama, Koichi Node, Shinichiro Ueda, Michio Shimabukuro
Published 2019-12-01

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving st...

by Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda
Published 2020-06-01

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus

by Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda
Published 2020-09-01

Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in Patients with Type 2 Diabetes? JPAD2 Cohort Study.

by Sadanori Okada, Takeshi Morimoto, Hisao Ogawa, Mio Sakuma, Hirofumi Soejima, Masafumi Nakayama, Hideaki Jinnouchi, Masako Waki, Yasuhiro Akai, Hitoshi Ishii, Yoshihiko Saito, Investigators for the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial
Published 2016-01-01